Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Vima Therapeutics Launches First Oral Therapy for Dystonia and Movement Disorders
Details : Vima is advancing VIM0423, a potential first-in-class oral therapy for dystonia that targets the underlying cause in the central nervous system.
Product Name : VIM0423
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 29, 2025